Sanara MedTech Inc.
NASDAQ:SMTIMedical - Instruments & Supplies
+$0.73 today
- Market cap
- $300.55M
- Beta
- 1.19
- P/E (TTM)
- -5.7
- EPS (TTM)
- -$3.86
Volume 0.07M
Average 0.06M
SMTI Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Sanara MedTech Inc.NASDAQ: SMTI
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$1.71M, compared with $366.03K a year earlier. Trailing-twelve-month accounts receivables was $1.96M.
Context
- Accounts receivables amounted to 3.9% of revenue in FY2025, down 1.3 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$1.71M or moves back toward the trailing-twelve-month quarterly average of $489.59K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 4.03M USD
- Year-over-year change
- +188.8%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.03M | +188.8% |
| FY2024 | 2024-12-31 | (4.54M) | -162.2% |
| FY2023 | 2023-12-31 | (1.73M) | +23.7% |
| FY2022 | 2022-12-31 | (2.27M) | -192.8% |
| FY2021 | 2021-12-31 | (774.81K) | — |
Accounts Receivables vs competitors
How SMTI compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +157.2% is the 2nd highest of 10, against a peer median of -80.6%.
- Accounts receivables amounts to 1.8% of revenue for SMTI, versus a peer median of 1.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.74M USD | +538.2% | -6.6% | 3.0% | |
| LTM Apr 2026 | CA$5.01M CAD | -470.6% | -28.9% | 0.7% | |
| LTM Mar 2026 | $2.58M USD | +153.0% | — | 1.2% | |
| LTM Mar 2026 | $2.56M USD | +32.8% | — | 0.9% | |
| LTM Mar 2026 | $1.96M USD | +157.2% | — | 1.8% | |
| LTM Mar 2026 | $1.26M USD | -98.3% | — | 21.9% | |
| LTM Mar 2026 | $1.14M USD | -118.2% | — | 1.4% | |
| LTM Mar 2026 | $1.05M USD | -72.7% | — | 1.5% | |
| LTM Mar 2026 | $980K USD | -404.3% | — | 3.1% | |
| LTM Mar 2026 | $622K USD | -80.6% | -37.3% | 0.2% | |
| Peer median (excluding SMTI) | — | -80.6% | -28.9% | 1.4% | |
Competitors are the stored peer set for SMTI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.99M) | (8.09M) | (4.44M) | (9.91M) | (27.66M) |
| Depreciation & Amortization | 596.98K | 2.37M | 3.68M | 4.92M | 28.56M |
| Deferred Income Tax | 0 | (5.84M) | 0 | 0 | 0 |
| Stock-Based Compensation | 2.67M | 2.7M | 3.44M | 4.44M | 718.71K |
| Change in Working Capital | (1.18M) | 517.62K | (3.28M) | (911.72K) | (3.84M) |
| Accounts Receivables | (774.81K) | (2.27M) | (1.73M) | (4.54M) | 4.03M |
| Inventory | (1.15M) | (517.27K) | (1.55M) | 1.44M | (431.33K) |
| Accounts Payables | 99.13K | (423.75K) | 575.15K | (471.21K) | 1.24M |
| Other Working Capital | 645.56K | 3.73M | (577.32K) | 2.66M | (8.68M) |
| Other Non-Cash Items | 1.1M | 2.79M | (2.64M) | 1.44M | 9.02M |
| Operating Cash Flow | (4.81M) | (5.55M) | (3.25M) | (23.78K) | 6.79M |
| Capital Expenditures | (750.45K) | (747.02K) | (265.25K) | (229.3K) | (4.63M) |
| Acquisitions (Net) | 0 | (2.52M) | (9.94M) | 0 | 0 |
| Purchases of Investments | (4.53M) | (250K) | 0 | (5.3M) | 9.48M |
| Sales of Investments | 0 | 0 | 0 | 0 | (2.96M) |
| Other Investing Activities | (578.59K) | (598.45K) | 650 | (1.1M) | (10.47M) |
| Investing Cash Flow | (5.28M) | (3.51M) | (10.21M) | (6.61M) | (8.36M) |
| Debt Repayment | 0 | 0 | 9.69M | 19.59M | 0 |
| Common Stock Issued | 28.94M | 0 | 911.37K | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (642.53K) | (627.35K) | (958.59K) | (2.15M) | (8.48M) |
| Financing Cash Flow | 28.3M | (627.35K) | 9.64M | 17.37M | (8.48M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 18.2M | (9.69M) | (3.81M) | 10.73M | (10.03M) |
| Free Cash Flow | (5.56M) | (6.3M) | (3.51M) | (253.08K) | 2.16M |
Sanara MedTech Inc.
NASDAQ:SMTI
Intrinsic Alpha fair value
Locked
Current Price
$32.73
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.